Background and Objective: Arterial Stiffness (AS) measured as pulse wave velocity has emerged in recent years as a hypertension mediated organ damage with independent prognostic value for Cardiovascular (CV) diseases that has also been discussed as a potential cause of Hypertension (HTN). The aim of this study is to (1) evaluate how measurement of AS modifies CV risk calculation by SCORE, (2) to measure the predictive value of AS for incident hypertension in normotensive patients, and (3) to analyze the association between control of HTN and presence of AS in sustained HTN. Patients and Methods: A longitudinal, prospective, observational trial under conditions of daily pharmaceutical and clinical practice will be conducted in approximately 60 community pharmacies of the Iberian Peninsula in normotensive and/or hypertensive patients entering a pharmacy spontaneously. In the first cross-sectional step, AS will be estimated with a semiautomatic, validated device (Mobil-O-Graph®, IEM), followed by a 10-item questionnaire. The patients will be referred to Primary Care for stratifying risk by SCORE tables and standard evaluation. In the second longitudinal step, patients will be asked to repeat the visit after 12 months. Discussion: This study aims to improve CV risk stratification and to investigate the potential of AS in predicting incident HTN in normotensive subjects. Besides, it will analyze the role of arterial stiffness as an associated factor to prevent control in sustained HTN in a setting of cooperation between community pharmacies and physicians in daily clinical practice.
Phytotherapy, an ancient practice based on the use of plant-based products, has recently seen a strong resurgence, driven by a growing preference for “natural” products. In the context of community pharmacy, it is presented as an alternative or complement to conventional treatments, especially for mild or chronic conditions, or as an adjuvant for serious illnesses. However, its use is not without risks, due to the variability in the composition of marketed products, the pharmacological action of their active ingredients, and the lack of uniform regulatory framework. There are different legal categories for these products, depending on their composition, indication, and scientific backing. Some, such as dietary supplements and medical devices, are available without medical supervision despite containing active ingredients used in prescription medications.
The growing use of phytotherapy and the increasing heterogeneity of available formulations require community pharmacists to critically assess marketed products based on criteria of quality, safety, and efficacy. To design an operational protocol to support community pharmacists in the evaluation and decision-making process regarding plant-based products. A consensus process was conducted by the SEFAC Fitoterapia Commission, involving the development and integration of structured checklists and the selection of open-access data sources. A decision tree was defined, starting from the legal classification, and an analytical framework for product evaluation was established. Finally, a rapid reporting template was designed for use in community pharmacy practice. The resulting protocol provides a structured approach to the evaluation of phytotherapeutic products, organized into five sections and a rapid report. It is based on a sequential assessment of legal classification, scientific evidence, quality, safety, and patient information. Its implementation is supported by official, reliable, and openly accessible databases available to community pharmacists. The proposed protocol facilitates consistent and traceable pharmaceutical decision-making by integrating regulatory and scientific information into a practical and applicable tool for community pharmacy.